SCHEMBL7675591

SCHEMBL7675591

O=C(Oc1nccc2ccccc12)c1cc2ccccc2oc1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F12 P00748 2/20 0.63
KDM4E B2RXH2 6/20 0.61
ALDH1A1 P00352 5/20 0.61
NPSR1 Q6W5P4 1/20 0.61
POLB P06746 3/20 0.59
MAPT P10636 3/20 0.59
HPGD P15428 2/20 0.59
HSD17B10 Q99714 1/20 0.59
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ATM Q13315 1/20 0.54
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAOB P27338 3/20 0.51
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CA1 P00915 1/20 0.51
CA3 P07451 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15733119 0.80 MEN1 (0.72) F12KDM4EALDH1A1NPSR1POLB
SCHEMBL15842719 0.76 KDM4E (1.00) F12KDM4EALDH1A1NPSR1POLB
SCHEMBL28812863 0.75 KDM4E (0.77) KDM4EALDH1A1NPSR1POLBMAPT
SCHEMBL7675587 0.75 KDM4E (0.67) F12KDM4EALDH1A1NPSR1POLB
SCHEMBL28302122 0.74 MAPT (0.44) KDM4EALDH1A1POLBMAPTHPGD
SCHEMBL15733005 0.74 KDM4E (0.79) F12KDM4EALDH1A1NPSR1POLB
SCHEMBL7681874 0.73 KDM4E (0.65) F12KDM4EALDH1A1NPSR1POLB
SCHEMBL76086 0.73 KDM4E (1.00) KDM4EALDH1A1NPSR1POLBMAPT
SCHEMBL4353465 0.72 KLK5 (0.51) F12ALDH1A1MAPTNPC1RAB9A
SCHEMBL6084594 0.72 KDM4E (0.80) F12KDM4EALDH1A1NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
US-9814696-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-14 US disclosed
EP-2731604-B1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIV PIERRE ET MARIE CURIE PARIS 6 (FR) 2017-04-19 EP disclosed
EP-2731604-B1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIV PIERRE ET MARIE CURIE PARIS 6 (FR) 2017-04-19 EP disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE DE LIEGE (BE) 2017-03-09 US disclosed
US-9532973-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-01-03 US disclosed
US-9532973-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-01-03 US disclosed
US-9006466-B2 Use of coumarin derivatives for the preparation of drugs for treating skin diseases UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2015-04-14 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-05-29 US disclosed
EP-2731604-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES Université Pierre et Marie Curie (Paris 6) (FR) 2014-05-21 EP disclosed
WO-2013010963-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2013-01-24 WO disclosed
WO-2013010963-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2013-01-24 WO disclosed
EP-2545916-A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases Universite Pierre Et Marie Curie - Paris 6 (FR) 2013-01-16 EP disclosed
EP-2545916-A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases Universite Pierre Et Marie Curie - Paris 6 (FR) 2013-01-16 EP disclosed
US-6355658-B1 COUMARIN ESTERS WITH ETHER GROUPS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148480-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, KLK1, SERPINC1 F12 15/4885KDM4E 2682/4885ALDH1A1 573/4885
US-20170065555-A1 USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES BDKRB1, SERPINC1, KLK1 F12 14/4885KDM4E 2644/4885ALDH1A1 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.